abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapelocationmap-pinminusnewsorganisationotheroverviewpluspreviewprofilerefreshnewssearchsecurityPathtagticktooltiptwitteruniversalityweb
Story

Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

In January 2014, the Innovative Pharmaceutical Association of South Africa (IPASA) was accused of planning and funding an advocacy campaign on behalf of its member companies. The campaign allegedly sought to oppose South Africa’s efforts to introduce intellectual property law reforms that would allow for patents belonging to IPASA’s member companies to be limited, and for cheaper generic versions to be produced.

In a leaked email, Merck and other members of IPASA discussed the strategy.

Media items on the IPASA campaign:

 

Business & Human Rights Resource Centre invited IPASA and its member companies to respond:

Members companies' responses & non-responses:

  • Abbott [We have invited Abbott to respond and will indicate here whether it responds]
  • Abbvie [We have invited Abbvie to respond and will indicate here whether it responds]
  • Alcon (part of Novartis) Novartis responded [PDF] on behalf of itself and Alcon
  • Allergan did not respond
  • Amgen [We have invited Amgen to respond and will indicate here whether it responds]
  • AstraZeneca response [PDF]
  • Baxter response [PDF]
  • Bayer response [PDF]
  • Boehringer-Ingelheim response [PDF]
  • Bristol-Myers Squibb referred us to IPASA
  • Covidien [We have invited Covidien to respond and will indicate here whether it responds]
  • Eli Lilly [We have invited Eli Lilly to respond and will indicate here whether it responds]
  • Ferring [We have invited Ferring to respond and will indicate here whether it responds]
  • Galderma response [PDF]
  • GE Health reffered us to IPASA
  • Johnson & Johnson response [PDF]
  • Merck (MSD) response [PDF]
  • Novartis response [PDF]
  • Novo Nordisk response [PDF] indicates it resigned from IPASA following campaign proposal:
  • Norgine [We have invited Norgine to respond and will indicate here whether it responds]
  • Pfizer referred us to IPASA
  • Roche response [PDF] indicates it resigned from IPASA following campaign proposal
  • Sanofi-Aventis [We have invited Sanofi-Aventis to respond and will indicate here whether it responds]
  • Servier [We have invited Servier to respond and will indicate here whether it responds]
  • Takeda referred us to IPASA

 

Novo Nordisk and Roche resigned from IPASA:

Company Responses

Abbott Laboratories

No Response

AbbVie

No Response

Allergan View Response
Amgen

No Response

AstraZeneca View Response
Baxter International View Response
Boehringer Ingelheim View Response
Bristol-Myers Squibb View Response
Covidien View Response
Eli Lilly View Response
Ferring Pharmaceuticals

No Response

Galderma View Response
GE Health (part of General Electric) View Response
Johnson & Johnson View Response
Norgine Pharmaceuticals View Response
Novartis View Response
Novo Nordisk (part of Novo Group) View Response
Pfizer View Response
Sanofi

No Response

Servier

No Response

Takeda Pharmaceutical View Response

Story Timeline